Atopic dermatitis: A review of recent advances in the field

Pediatric Health

Volumn 2, Issue 6, 2008, Pages 733-747

  Lam, Joseph ^a   Friedlander, Sheila F ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Atopic dermatitis; Atopy; Eczema; Management strategies; Topical calcineurin inhibitors; Topical steroids

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; B7 ANTIGEN; CALCINEURIN INHIBITOR; CASEIN; CATHELICIDIN; CD86 ANTIGEN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN A; EMOLLIENT AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FILAGGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; RITUXIMAB; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL DISCOMFORT; AGRANULOCYTOSIS; ALLERGIC RHINITIS; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; ATOPY; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BREAST FEEDING; CANCER RISK; CARDIOMYOPATHY; CHROMOSOME 5Q; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG PULSE THERAPY; DRUG SAFETY; EDUCATION PROGRAM; ENVIRONMENTAL FACTOR; ENZYME DEFICIENCY; EPIDERMIS CELL; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEREDITY; HERPES SIMPLEX; HOMEOPATHY; HONEY; HUMAN; HYDRATION; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INFLAMMATORY DENDRITIC EPIDERMAL CELL; LANGERHANS CELL; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; MALAISE; MASSAGE; MYALGIA; NAUSEA; NONHUMAN; PAPULE; PERMEABILITY BARRIER; PHOTOTHERAPY; PREVALENCE; PRIMARY PREVENTION; PRURITUS; PSORIASIS; QUALITY OF LIFE; REHABILITATION CARE; RESPIRATORY DISTRESS SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN ATROPHY; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; SYMPTOMATOLOGY; T LYMPHOCYTE ACTIVATION; TEA; TH2 CELL; THIOPURINE METHYLTRANSFERASE DEFICIENCY; VOMITING; WET WRAP THERAPY; XEROSIS;

EID: 70349646630     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/17455111.2.6.733     Document Type: Review

References (128)

1. Tay Y-K, Kong K-H, Khoo L et al.: The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br. J. Dermatol. 146, 101-106 (2002).
2. Yura A, Shimizu T: Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka prefecture, Japan, from 1985 to 1997. Br. J. Dermatol. 145, 966-973 (2001).
3. Stensen L, Thomsen SF, Backer V: Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc. 29(4), 392-396 (2008).
4. William H, Flohr C: How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J. Allergy Clin. Immunol. 118, 209-213 (2006).
5. Ergin S, Ozşahin A, Erdoǧan BS, Aktan S, Zencir M: Epidemiology of atopic dermatitis in primary schoolchildren in Turkey. Pediatr. Dermatol. 25(3), 399-340 (2008).
6. Schultz Larsen F, Diepgen T, Svensson A: The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J. Am. Acad. Dermatol. 34, 760-764 (1996).
7. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG: The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 30, 35-39 (1994).
8. Illi S, von Mutius E, Lau S et al.: The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J. Allergy Clin. Immunol. 113, 925-931 (2004).
9. Schultz Larsen F: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J. Am. Acad. Dermatol. 28, 719-723 (1993).
10. MacLean J, Eidelman F: The genetics of atopy and atopic eczema. Arch. Dermatol. 137(11), 1474-1476 (2001).
11. Cookson W, Ubhi B, Lawrence R et al.: Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat. Genet. 27, 372-373 (2001).
12. Cookson W, Moffatt M. The genetics of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2, 383-387 (2002).
13. Walley A, Chavanas S, Moffatt M et al.: Gene polymorphism in Netherton and common atopic disease. Nat. Genet. 29(2), 175-178 (2001).
14. Möhrenschlager M, Darsow U, Schnopp C, Ring J: Atopic eczema: what's new? J. Eur. Acad. Dermatol. Venereol. 20, 503-513 (2006).
15. Tamura K, Suzuki M, Arakawa H, Tokuyama K, Morikawa A: Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int. Arch. Allergy Immunol. 131, 33-38 (2003).
16. Novak N, Kruse S, Kraft S et al.: Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J. Invest. Dermatol. 119, 870-875 (2002).
17. Weidinger S, Klopp N, Wagenpfeil S et al.: Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J. Med. Genet. 41, 658-663 (2004).
18. Lipozenciç J, Wolf R: Atopic dermatitis: an update and review of the literature. Dermatol. Clin. 25(4), 605-612 (2007).
19. Hoffjan S, Epplen JT: The genetics of atopic dermatitis: recent findings and future options. J. Mol. Med. 83, 682-692 (2005).
20. Bieber T: Atopic Dermatitis. N. Engl. J. Med. 358(14), 1483-1494 (2008).
21. Sandilands A, Smith FJ, Irvine AD, McLean WH: Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J. Invest. Dermatol. 127(6), 1282-1284 (2007).
22. Weidinger S, Illig T, Baurecht H et al.: Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations J. Allergy Clin. Immunol. 118, 214-219 (2006).
23. Marenholz I, Nickel R, Ruschendorf F et al.: Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march J. Allergy Clin. Immunol. 118, 866-871 (2006).
24. O'Regan GM, Sandilands A, McLean WH, Irvine AD: Filaggrin in atopic dermatitis. J. Allergy Clin. Immunol. (2008) (Epub ahead of print).
25. Sandilands A, Terron-Kwiatkowski A, Hull PR et al.: Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat. Genet. 39, 650-654 (2007).
26. O'Regan GM, Irvine AD: The role of filaggrin loss-of-function mutations in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 8(5), 406-410 (2008).
27. Irvine A: Fleshing out filaggrin phenotypes. J. Invest. Dermatol. 127, 504-507 (2007).
28. Henderson J, Northstone K, Lee S et al.: The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J. Allergy Clin. Immunol. 121, 872-877 (2008).
29. Weidinger S, O'Sullivan M, Illig T et al.: Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J. Allergy Clin. Immunol. 121, 1203-1209 (2008).
30. Morar N, Willis-Owen SA, Moffatt MF, Cookson WO: The genetics of atopic dermatitis. J. Allergy Clin. Immunol. 118(1), 24-23 (2006)
31. Chien YH, Hwu WL, Chiang BL: The genetics of atopic dermatitis. Clin. Rev. Allergy Immunol. 33(3), 178-190 (2007).
32. Bradley M, Soderhall C, Luthman H et al.: Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum. Mol. Genet. 11, 1539-1548 (2002).
33. Haagerup A, Bjerke T, Schiotz PO et al.: Atopic dermatitis - a total genome-scan for susceptibility genes. Acta Derm. Venereol. 84, 346-352 (2004).
34. Lee YA, Wahn U, Kehrt R et al.: A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet. 26, 470-473 (2000).
35. Enomoto H, Noguchi E, Iijima S et al.: Single nucleotide polymorphism-based genome-wide linkage analysis in Japanese atopic dermatitis families. BMC Dermatol. 7, 5 (2007).
36. Sator PG, Schmidt JB, Honigsmann H: Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J. Am. Acad. Dermatol. 48, 352-358 (2003).
37. Nagelkerken L, Verzaal P, Lagerweij T et al.: Development of atopic dermatitis in mice transgenic for human apolipoprotein C1. J. Invest. Dermatol. 128(5), 1165-1172 (2008)
38. Akdis CA, Akdis M, Bieber T et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 61(8), 969-987 (2006).
39. Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic dermatitis. J. Clin. Invest. 94, 870-876 (1994).
40. Lugovic L, Lipozencic J, Jakic-Razumovic J: Prominent involvement of activated Th1-subset of T-cells and increased expression of receptor for IFN-γ on keratinocytes in atopic dermatitis acute skin lesions. Int. Arch. Allergy Immunol. 137, 125-133 (2005).
41. Toda M, Leung DY, Molet S et al.: Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J. Allergy Clin. Immunol. 111, 875-881 (2003).
42. Taha RA, Minshall EM, Leung DY et al.: Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J. Allergy Clin. Immunol. 105, 1002-1007 (2000).
43. Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S: Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J. Allergy Clin. Immunol. 113, 940-948 (2004).
44. Elston D: The hygience hypothesis and atopy: Bring back the parasites? J. Am. Acad. Dermatol. 54, 172-179 (2006).
45. Harris JM, Williams HC, White C et al.: Early allergen exposure and atopic eczema. Br. J. Dermatol. 156(4), 698-704 (2007).
46. Ong PY, Ohtake T, Brandt C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151-1160 (2002).
47. Peng WM, Jenneck C, Bussmann C et al.: Risk factors of atopic dermatitis patients for eczema herpeticum. J. Invest. Dermatol. 127(5), 1261-1263 (2007).
48. Leung DY: Infection in atopic dermatitis. Curr. Opin. Pediatr. 15, 399-404 (2003).
49. Leyden JJ, Marples RR, Kligman AM: Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol. 90(5), 525-530 (1974).
50. Aly R, Maibach HI, Shinefield HR: Microbial flora of atopic dermatitis. Arch. Dermatol. 113(6), 780-782 (1977).
51. Hofer MF, Lester MR, Schlievert PM, Leung DY: Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in peripheral blood mononuclear cells from patients with atopic dermatitis. Clin. Exp. Allergy 25(12), 1218-1227 (1995).
52. Fukushima H, Hirano T, Shibayama N et al.: The role of immune response to Staphylococcus aureus superantigens and disease severity in relation to the sensitivity to tacrolimus in atopic dermatitis Int. Arch. Allergy Immunol. 141, 281-289 (2006).
53. Hanifin J, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm. Venereol. 92, 44-47 (1980).
54. Williams HC, Burney PG, Pembroke AC et al.: The UK working party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br. J. Dermatol. 131, 406-416 (1994).
55. Williams HC, Burney PG, Pembroke AC, Hay RJ: Validation of UK diagnostic criteria for atopic dermatitis in a population setting. Br. J. Dermatol. 135, 12-17 (1996).
56. Saeki H, Iizuka H, Mori Y et al.: Community validation of the UK diagnostic criteria for atopic dermatitis in Japanese elementary schoolchildren. J. Dermatol. Sci. 47(3), 227-231 (2007).
57. Chalmers DA, Todd G, Saxe N et al.: Validation of the UK Working Party diagnostic criteria for atopic eczema in a Xhosa-speaking African population. Br. J. Dermatol. 156(1), 111-116 (2007).
58. Firooz A, Davoudi SM, Farahmand AN et al.: Validation of the diagnostic criteria for atopic dermatitis. Arch. Dermatol. 135(5), 514-516 (1999).
59. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI: Diagnostic criteria for atopic dermatitis: a systematic review. Br. J. Dermatol. 158(4), 754-765 (2008).
60. De D, Kanwar AJ, Handa S: Comparative efficacy of Hanifin and Rajka's criteria and the UK working party's diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India. J. Eur. Acad. Dermatol. Venereol. 20, 853-859 (2006).
61. Johansson SG, Bieber T, Dahl R et al.: Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, October 2003. J. Allergy Clin. Immunol. 113, 832-836 (2004).
62. Staab D, Ruden U, Kehrt R et al.: The impact of childhood atopic dermatitis on quality of life of family. Dematol. Psychosom. 1, 173-178 (2000).
63. Staab D, Diepgen TL, Fartasch M et al.: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. Br. Med. J. 332(7547), 933-938 (2006).
64. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P: Pediatric atopic eczema: the impact of an educational intervention. Pediatr. Dermatol. 23(5), 428-436 (2006)
65. Snijders BE, Thijs C, van Ree R, van den Brandt PA: Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA birth cohort study. Pediatrics 122(1), E115-E122 (2008)
66. Schafer T: Prevention of atopic eczema. Evidence based guidelines. Hautarzt 56, 232-240 (2005).
67. Gdalevich M, Mimouoni D, David M, Mimouni M: Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J. Am. Acad. Dermatol. 45, 520-527 (2001).
68. Laubereau B, Brockow I, Zirngibl A et al.: Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life: results from the GINI-birth cohort study. J. Pediatr. 144, 602-607 (2004).
69. Duncan JM, Sears MR: Breastfeeding and allergies: time for a change in paradigm? Curr. Opin. Allergy Clin. Immunol. 8(5), 398-405 (2008).
70. von Berg A, Koletzko S, Grubl A et al.: The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J. Allergy Clin. Immunol. 111, 533-540 (2003).
71. von Berg A, Koletzko S, Filipiak-Pittroff B et al.: Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three-year results of the German Infant Nutritional Intervention Study. J. Allergy Clin. Immunol. 119(3), 718-725 (2007).
72. Greer FR, Sicherer SH, Burks AW: Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 121(1), 183-191 (2008).
73. Muraro A, Dreborg S, Halken S et al.: Dietary prevention of allergic diseases in infants and small children. Part III: critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr. Allergy Immunol. 15, 291-230 (2004).
74. Kramer MS, Kakuma R: Optimal duration of exclusive breastfeeding. Cochrane Database Syst. Rev. (1), CD003517 (2002).
75. Dunlop AL, Reichrtova E, Palcovicova L et al.: Environmental and dietary risk factors for infantile atopic eczema among a Slovak birth cohort. Pediatr. Allergy Immunol. 17(2), 103-111 (2006).
76. Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M: Long-term follow-up of atopic dermatitis: retrospective ana lysis of related risk factors and association with concomitant allergic diseases. Pediatr. Allergy Immunol. 17, 103-111 (2006).
77. García C, El-Qutob D, Martorell A et al.: Sensitization in early age to food allergens in children with atopic dermatitis. Allergol. Immunopathol. (Madr.) 35(1), 15-20 (2007).
78. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA: Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101, E8 (1998).
79. Rowlands D, Tofte SJ, Hanifin JM: Does food allergy cause atopic dermatitis? Food challenge testing to dissociate eczematous from immediate reactions. Dermatol. Ther. 19(2), 97-103 (2006).
80. Hanifin J, Gupta AK, Rajagopalan R: Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br. J. Dermatol. 147(3), 528-537 (2002).
81. Nuutinen P, Riekki R, Parikka M et al.: Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br. J. Dermatol. 148(1), 39-45 (2003).
82. Orlow S: Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr. Drugs. 9(5), 289-299 (2007).
83. Spergel JM, Leung DY: Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr. Allergy Asthma Rep. 6(4), 270-274 (2006).
84. Munzenberger PJ, Montejo JM: Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 27(7), 1020-1028 (2007).
85. Hon KL, Wong KY, Cheung LK et al.: Efficacy and problems associated with using a wet-wrap garment for children with severe atopic dermatitis. J. Dermatol. Treat. 18(5), 301-305 (2007).
86. Foelster-Holst R, Nagel F, Zoellner P, Spaeth D: Efficacy of crisis intervention treatment with topical corticosteroid prednicarbate with and without partial wet-wrap dressing in atopic dermatitis. Dermatology 212, 66-69 (2006).
87. Devillers AC, Oranje AP: Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br. J. Dermatol. 154(4), 579-585 (2006).
88. Walters IB, Ozawa M, Cardinale I et al.: Narrowband (312 nm) UV-B suppresses interferon γ and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level. Arch. Dermatol. 139, 155-161 (2003)
89. Schauber J, Gallo RL; Antimicrobial peptides and the skin immune defense system. J. Allergy Clin. Immunol. 122(2), 261-266 (2008).
90. Clayton TH, Clark SM, Turner D, Goulden V: The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin. Exp. Dermatol. 32(1), 28-33 (2007).
91. Pasica, Ceovic R, Lipozencic J et al.: Phototherapy in pediatric patients. Pediatr. Dermatol. 20(1), 71-77 (2003).
92. Ibbotson SH, Bilsland D, Cox NH et al.: An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br. J. Dermatol. 151, 283-297 (2004).
93. Collins P, Ferguson J: Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br. J. Dermatol. 133, 653-655 (1995).
94. Tay YK, Morelli JG, Weston WL: Experience with UVB phototherapy in children. Pediatr. Dermatol. 13, 406-409 (1996).
95. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D: Narrowband ultraviolet B (UVB) phototherapy in children. Clin. Exp. Dermatol. 31, 196-199 (2006).
96. Lee E, Koo J, Berger T: UVB phototherapy and skin cancer risk: a review of the literature. Int. J. Dermatol. 44, 355-360 (2005).
97. Gong JQ, Lin L, Lin T et al.: Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br. J. Dermatol. 155, 680-687 (2006).
98. Friedmann PS, Palmer R, Tan E, Ogboli M et al.: A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin. Exp. Allergy. 37(10), 1536-1540 (2007).
99. Veien NK, Busch-Sørensen M, Stausbøl-Grøn B: Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 53(1), 147-149 (2005).
100. Silverberg NB, Paller AS: Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. J. Am. Acad. Dermatol. 50(3), 485-486 (2004).
101. Bunikowski R, Staab D, Kussebi F et al.: Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr. Allergy Immunol. 12(4), 216-223 (2001).
102. Leonardi S, Marchese G, Rotolo N, Miraglia Del Giudice M, La Rosa M: Cyclosporin is safe and effective in severe atopic dermatitis of childhood. Report of three cases. Minerva Pediatr. 56(2), 231-237 (2004).
103. Harper JI, Berth-Jones J, Camp RD et al.: Cyclosporin for atopic dermatitis in children. Dermatology 203(1), 3-6 (2001).
104. Harper JI, Ahmed I, Barclay G et al.: Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br. J. Dermatol. 142(1), 52-58 (2000).
105. Berth-Jones J, Finlay AY, Zaki I et al.: Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J. Am. Acad. Dermatol. 34(6), 1016-1021 (1996).
106. Schmitt J, Schmitt N, Meurer M: Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 21(5), 606-619 (2007).
107. Pedreira CC, King E, Jones G et al.: Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema. Pediatr. Dermatol. 24(6), 613-620 (2007).
108. Murphy LA, Atherton DJ: Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr. Dermatol. 20(6), 531-534 (2003).
109. Murphy LA, Atherton D: A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br. J. Dermatol. 147(2), 308-315 (2002).
110. Knowles SR, Gupta AK, Shear NH, Sauder D: Azathioprine hypersensitivity-like reactions - a case report and a review of the literature. Clin. Exp. Dermatol. 20, 353-356 (1995).
111. Smith L, Morris M, Wong W: Renal transplantation in children; the Auckland experience 1980-1996. N. Z. Med. J. 110, 202-204 (1997).
112. Heller M, Shin HT, Orlow SJ, Schaffer JV: Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br. J. Dermatol. 157(1), 127-132 (2007).
113. Behrend M: Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 24, 645-663 (2001).
114. Hantash B, Fiorentino D: Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch. Dermatol. 142, 109-110 (2006).
115. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ: An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br. J. Dermatol. 156(2), 346-351 (2007).
116. Martin-Mateos MA: Monoclonal antibodies in pediatrics: use in prevention and treatment. Allergol. Immunopathol. (Madr.) 35(4), 145-150 (2007).
117. Forman SB, Garrett AB: Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FceRI. Cutis 80(1), 38-40 (2007).
118. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol. 121(1), 122-128 (2008).
119. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S: Etanercept is minimally effective in 2 children with atopic dermatitis. J. Am. Acad. Dermatol. 53(2), 358-359 (2005).
120. Zhang W, Leonard T, Bath-Hextall F et al.: Chinese herbal medicine for atopic eczema. Cochrane Database Syst. Rev. 2, CD002291 (2005).
121. Sheehan MP, Atherton DJ: A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br. J. Dermatol. 126, 179 -184 (1992).
122. Sheehan MP, Atherton DJ: One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br. J. Dermatol. 130, 488-493 (1994).
123. Hon KL, Leung TF, Ng PC et al.: Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br. J. Dermatol. 157, 357-363 (2007).
124. Fung AY, Look PC, Chong LY, But PP, Wong E: A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int. J. Dermatol. 38, 387-392 (1999).
125. Al-Waili NS: Topical application of natural honey, beeswax and olive oil mixture for atopic dermatitis or psoriasis: partially controlled, single-blinded study. Complement Ther. Med. 11, 226 -234 (2003).
126. Itamura R, Hosoya R: Homeopathic treatment of Japanese patients with intractable atopic dermatitis. Homeopathy 92, 108-114 (2003).
127. Mevorah B, Orion E, Matz H, Wolf R: Cutaneous side effects of alternative therapy. Dermatol. Ther. 16, 141 -149 (2003).
128. Bukutu C, Deol J, Shamseer L, Vohra S: Complementary, holistic, and integrative medicine: atopic dermatitis. Pediatr. Rev. 28(12), E87-E94 (2007).